Cancer‐related pain: A bidirectional modulator of cancer progression
Clinical and Translational Medicine · 2026
DOI: 10.1002/ctm2.70817 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Medicine, 2026. Verfasst von Junzhe He und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China. Hauptthemen laut MEDLINE: Cancer Pain, Disease Progression, Neoplasms. Die Arbeit nennt 295 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Key Clinical Specialty, Shanghai Eye Disease Research Center, Innovative Research Team of High-level Local Universities in Shanghai.
Abstract (Originalsprache)
Background
Cancer‐related pain (CRP), with a high prevalence and prognostic value in malignancies, is not only a passive phenomenon but rather engages in a bidirectional crosstalk with cancer progression. Main Topics This review focuses on the intricate reciprocal relationship between CRP and cancer progression, delineating how advanced cancers promote CRP directly through tissue destruction, invasion and inflammation, or indirectly via inflammatory, neural, stromal and metabolic components within the tumour microenvironment. However, controversies remain in the field, such as the ambiguous role of sensory neurons in cancer progression and the potential pro‐tumorigenic risk of opioids. Notably, CRP regulates cancer progression through local pain‐associated mediators (e.g., CGRP, SP), the pain‐stress axis, central nuclei‐mediated peripheral immune modulation, sensory‐sympathetic/vagal circuits and direct effects on tumour biology.
Conclusion
Future research should further elucidate the mechanistic interplay between pain and cancer, as targeting CRP may offer novel therapeutic opportunities for anti‐cancer treatment. Highlights CRP and tumour progression engage in a dynamic, bidirectional circuit mediated by multiple mechanisms in neuroimmunology and cancer neuroscience. Analgesic interventions may affect tumour progression, while anticancer therapies can influence pain. Targeting pain in cancer may have promising therapeutic value in cancer progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
- Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, People's Republic of China.
- Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
ORCID-Profile: Biao Yan, Peiwei Chai, Renbing Jia
Förderung
- National Natural Science Foundation of China
- Shanghai Key Clinical Specialty, Shanghai Eye Disease Research Center
- Innovative Research Team of High-level Local Universities in Shanghai
Zitieren
APA
He, J., Zhang, Y., Liu, Q., Yan, B., Chai, P., & Jia, R. (2026). Cancer‐related pain: A bidirectional modulator of cancer progression. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70817
Vancouver
He J, Zhang Y, Liu Q, Yan B, Chai P, Jia R. Cancer‐related pain: A bidirectional modulator of cancer progression. Clinical and Translational Medicine. 2026. doi:10.1002/ctm2.70817
BibTeX
@article{He2026,
author = {He, Junzhe and Zhang, Yu and Liu, Qian and Yan, Biao and Chai, Peiwei and Jia, Renbing},
title = {Cancer‐related pain: A bidirectional modulator of cancer progression},
journal = {Clinical and Translational Medicine},
year = {2026},
doi = {10.1002/ctm2.70817}
}
EUVIMED